QCG
BMY icon

Quadrant Capital Group’s Bristol-Myers Squibb BMY Stock Holding History

Quadrant Capital Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Buy
34,231
+12,847
+60% +$749K 0.06% 260
2025
Q4 		$1.15M Sell
21,384
-11,088
-34% -$533K 0.03% 476
2025
Q3 		$1.46M Sell
32,472
-13,214
-29% -$617K 0.05% 348
2025
Q2 		$2.11M Buy
45,686
+11,146
+32% +$547K 0.08% 213
2025
Q1 		$2.11M Buy
34,540
+21,624
+167% +$1.26M 0.08% 173
2024
Q4 		$731K Buy
12,916
+1,096
+9% +$61.2K 0.05% 248
2024
Q3 		$612K Buy
11,820
+3,830
+48% +$180K 0.04% 293
2024
Q2 		$332K Sell
7,990
-3,529
-31% -$158K 0.02% 454
2024
Q1 		$625K Sell
11,519
-3,007
-21% -$153K 0.05% 277
2023
Q4 		$745K Sell
14,526
-2,545
-15% -$134K 0.06% 219
2023
Q3 		$991K Sell
17,071
-731
-4% -$44.8K 0.1% 149
2023
Q2 		$1.14M Sell
17,802
-4,026
-18% -$270K 0.11% 128
2023
Q1 		$1.51M Sell
21,828
-1,582
-7% -$112K 0.16% 90
2022
Q4 		$1.68M Buy
23,410
+6,071
+35% +$458K 0.19% 80
2022
Q3 		$1.23M Buy
17,339
+404
+2% +$29.3K 0.16% 90
2022
Q2 		$1.3M Buy
16,935
+1,054
+7% +$80.3K 0.18% 87
2022
Q1 		$1.16M Buy
15,881
+2,514
+19% +$169K 0.14% 103
2021
Q4 		$833K Sell
13,367
-370
-3% -$21.7K 0.1% 150
2021
Q3 		$813K Sell
13,737
-264
-2% -$17.4K 0.11% 133
2021
Q2 		$936K Sell
14,001
-1,535
-10% -$100K 0.14% 113
2021
Q1 		$981K Buy
15,536
+2,516
+19% +$157K 0.16% 98
2020
Q4 		$808K Buy
13,020
+460
+4% +$28.3K 0.15% 104
2020
Q3 		$757K Buy
12,560
+705
+6% +$42.4K 0.17% 95
2020
Q2 		$697K Sell
11,855
-16,113
-58% -$964K 0.15% 107
2020
Q1 		$1.55M Sell
27,968
-299
-1% -$18.3K 0.26% 72
2019
Q4 		$1.78M Buy
28,267
+11,805
+72% +$676K 0.21% 78
2019
Q3 		$822K Buy
16,462
+3,826
+30% +$180K 0.13% 133
2019
Q2 		$559K Sell
12,636
-901
-7% -$42K 0.09% 201
2019
Q1 		$627K Buy
13,537
+3,665
+37% +$183K 0.11% 153
2018
Q4 		$494K Sell
9,872
-572
-5% -$30.7K 0.13% 120
2018
Q3 		$630K Buy
10,444
+411
+4% +$24.4K 0.18% 94
2018
Q2 		$542K Sell
10,033
-781
-7% -$42.2K 0.19% 97
2018
Q1 		$662K Sell
10,814
-325
-3% -$20.9K 0.24% 78
2017
Q4 		$670K Sell
11,139
-61
-0.5% -$3.81K 0.27% 75
2017
Q3 		$696K Buy
11,200
+149
+1% +$8.7K 0.29% 71
2017
Q2 		$568K Sell
11,051
-311
-3% -$16.9K 0.25% 77
2017
Q1 		$607K Sell
11,362
-41
-0.4% -$2.25K 0.27% 74
2016
Q4 		$654K Buy
11,403
+3,718
+48% +$203K 0.33% 59
2016
Q3 		$406K Sell
7,685
-869
-10% -$55.8K 0.26% 68
2016
Q2 		$618K Buy
8,554
+665
+8% +$47K 0.43% 42
2016
Q1 		$495K Buy
7,889
+434
+6% +$27.4K 0.32% 56
2015
Q4 		$506K Sell
7,455
-176
-2% -$11.6K 0.35% 60
2015
Q3 		$447K Buy
7,631
+1,034
+16% +$65.6K 0.31% 62
2015
Q2 		$436K Buy
+6,597
New +$435K 0.28% 67

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quadrant Capital Group's BMY Position: Q1 2026 in Review

Quadrant Capital Group increased its Bristol-Myers Squibb (BMY) stake by 60% in Q1 2026, buying an estimated $749K and bringing the position to 34,231 shares worth $2.08M. The position accounts for 0.06% of the portfolio, ranked #260.

Quadrant Capital Group first reported a position in BMY in Q2 2015 and has held it in 44 quarters since. The position peaked at $2.11M in Q2 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Quadrant Capital Group held 34,231 shares of Bristol-Myers Squibb worth $2.08M as of Q1 2026.
  • Quadrant Capital Group bought 12,847 Bristol-Myers Squibb shares in Q1 2026, an estimated $749K.
  • Bristol-Myers Squibb made up 0.06% of Quadrant Capital Group's portfolio in Q1 2026, its #260 holding.
  • Quadrant Capital Group first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 44 quarters since.
  • Quadrant Capital Group's Bristol-Myers Squibb position peaked at $2.11M in Q2 2025.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.